OncoMatch/Clinical Trials/NCT06130579

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

Is NCT06130579 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies IFN-Α for myeloid leukemia.

Phase 2RecruitingPeking University People's HospitalNCT06130579Data as of May 2026

Treatment: IFN-Α — To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation. To explore the efficacy of interferon-α in reducing the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Myelodysplastic Syndrome

Biomarker criteria

Required: TP53 mutation

Prior therapy

Must have received: allogeneic hematopoietic stem cell transplantation

within 2 months after receiving the first allogeneic hematopoietic stem cell transplantation

Lab requirements

Blood counts

absolute neutrophil count (anc) greater than 0.5×10^9/l

Kidney function

creatinine < 1.5mg/dl

Cardiac function

cardiac ejection index >55%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify